Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Label Generation and Sample Barcode Management – V 2.0

Posted on By

BA-BE Studies: SOP for Label Generation and Sample Barcode Management – V 2.0

Standard Operating Procedure for Label Generation and Sample Barcode Management in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/121/2025
Supersedes SOP/BA-BE/121/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for generating, assigning, and managing labels and barcodes for biological samples collected during Bioavailability/Bioequivalence (BA/BE) studies, ensuring sample traceability and data integrity.

2. Scope

This SOP applies to the Clinical and Bioanalytical staff involved in the preparation, identification, labeling, and tracking of plasma, blood, and other biological samples in BA/BE studies.

3. Responsibilities

  • Label Coordinator: Prepares and verifies study-specific labels and barcodes before study initiation.
  • Clinical Research Coordinator: Ensures correct labels are used at the time of sample collection.
  • Bioanalytical Staff: Confirms barcode matches with sample ID before analysis or storage.
  • QA Officer: Reviews label issuance logs and audits labeling process.
See also  BA-BE Studies: SOP for Third-Party Vendor Qualification (Labs, Courier) - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that sample labeling and barcode management is conducted in accordance with protocol, GCP, and data integrity standards.

5. Procedure

5.1 Label Design and Structure

  1. Each sample label shall contain the following fields:
    • Volunteer ID
    • Study Code
    • Sampling Time Point
    • Period Number
    • Sample Type (e.g., Plasma, Serum)
    • Barcode (Code 128 or 2D)
  2. Standard format: [StudyCode]-[VolID]-[Period]-[Time]-[SampleType]

5.2 Label Generation

  1. Labels are generated using validated label printing software.
  2. Use Annexure-1: Label Generation Request Form to initiate request.
  3. Ensure printer calibration and alignment before label generation.
  4. Print labels in batches per subject, sorted by timepoint and period.

5.3 Label Verification and Documentation

  1. After printing:
    • Randomly select 5% of labels for visual inspection.
    • Verify field accuracy and barcode readability.
    • Record verification in Annexure-2: Label Verification Log.
  2. Discard misprinted or damaged labels and log in Annexure-3: Label Rejection Log.
See also  BA-BE Studies: SOP for Periodic Clinical Safety Assessments - V 2.0

5.4 Label Application

  1. Labels must be applied:
    • Before sample collection (preferred)
    • Immediately post-collection if pre-labeling is not feasible
  2. Ensure labels are affixed straight and do not overlap on conical tubes or cryovials.
  3. Use gloves while handling labels to avoid contamination or smudging.

5.5 Barcode Tracking

  1. Scan barcodes during:
    • Sample collection
    • Centrifugation and aliquoting
    • Storage and transport
  2. Link barcode scans to the Sample Tracking Log (Annexure-4).

5.6 Archival and Backup

  1. Maintain soft copies of label batches used in each study.
  2. Store printed label sheets (used and rejected) in a designated file.
  3. QA to archive logs and audit trails of barcode tracking systems.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • ID: Identification
  • SOP: Standard Operating Procedure

7. Documents

  1. Label Generation Request Form – Annexure-1
  2. Label Verification Log – Annexure-2
  3. Label Rejection Log – Annexure-3
  4. Sample Tracking Log – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • 21 CFR Part 11 – Electronic Records and Signatures
  • WHO Guidelines for Clinical Sample Management
See also  BA-BE Studies: SOP for Handling Confidentiality Agreements with Study Sites - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Label Generation Request Form

Date Requested By Study Code No. of Subjects Timepoints
15/04/2025 Rajesh Kumar BE-121 24 0, 1, 2, 4, 8, 12 hrs

Annexure-2: Label Verification Log

Date Batch No. Verified By No. Checked Result
16/04/2025 LGL-BE121-01 Sunita Reddy 12 Acceptable

Annexure-3: Label Rejection Log

Date Label ID Issue Destroyed By
16/04/2025 BE121-V06-P1-0hr Smudged print Meena Joshi

Annexure-4: Sample Tracking Log

Date Volunteer ID Sample Type Barcode Location Scanned By
17/04/2025 VOL-121-008 Plasma BE121-V08-P2-4hr Freezer Rack B1 Ajay Verma

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP Release GCP Compliance QA Head
17/04/2025 2.0 Added barcode scanning and tracking procedures Inspection Recommendation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Elixir Department: SOP for Identification of Critical vs Non-Critical Materials – V 2.0
Next Post: API Manufacturing: SOP for Control Sample Collection and Labeling – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version